Dr. Reddy's Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+3.2%+16.5%+13.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−24.5%+7.7%+25.0%
−35.8%+5.9%+26.8%
−27.4%+2.6%+23.8%
−25.7%−79.7%+23.5%
+17.6%+27.2%+20.4%
+12.7%+20.1%+21.3%
+22.2%+2.2%−22.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,345.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+13.5+16.5+3.2—
EBITDA Growth—+25.0+7.7-24.5—
EBIT Growth—+26.8+5.9-35.8—
Net Income Growth—+23.8+2.6-27.4—
EPS Growth—+23.5-79.7-25.7—
Total Assets Growth—+20.4+27.2+17.6—
Total Equity Growth—+21.3+20.1+12.7—
Cash from Operations Growth—-22.8+2.2+22.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.